메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

CHENGDU, China, Aug. 19, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimab for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) have been published in Nature Medicine (Impact Factor: 58.7). The publication highlighted initial findings from the Phase II OptiTROP-Lung01 study, evalua
- 김갑성 기자
- 2025-08-19 20:09
Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities

Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation Plan to host Investor Day in 2026 Initiatives follow constructive engagement with Elliott Management GALWAY, Ireland, Aug. 19, 2025 -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the Medtronic Board of Directors has appointed John Groetelaars and Bill Jellison
- 김갑성 기자
- 2025-08-19 18:46
HoneyNaps Launches Cloud Version of AI Sleep Diagnostic Software "SOMNUM™" at SLEEP 2025

[ 메디채널 김갑성 기자 ] HIPAA-compliant cloud-based service provides diagnostic reports via the web with no installation required AI-powered trial service offered, highlighting potential for hospital-specific integration Presented performance of heart rate-based sleep stage estimation algorithm through oral and poster presentations BOSTON, Aug. 19, 2025 -- HoneyNaps, a medical AI diagnostics company, showcased both its technological capabilities and research achievements at SLEEP 2025, the world's largest sleep medicine conference held in Seattle, USA, from June 8 to 11. SLEEP 2
- 김갑성 기자
- 2025-08-19 18:00
Dubai Humanitarian: Powerful New Documentary Reveals World's Largest Humanitarian Logistics Hub

- 'Coming Together: The Dubai Humanitarian Story' provides behind-the-scenes look inside the heart of global disaster response facility - Launches on World Humanitarian Day, 19 August 2025 - First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank DUBAI, UAE, Aug. 19, 2025 -- Dubai Humanitarian, the world's largest humanitarian logistics hub, has unveiled a new documentary, Coming Together: The Dubai Humanitarian Story - a gripping behind-the-scenes look at the premier disaster response faci
- 김갑성 기자
- 2025-08-19 17:00
Dubai Humanitarian: Powerful New Documentary Reveals World's Largest Humanitarian Logistics Hub

- 'Coming Together: The Dubai Humanitarian Story' provides behind-the-scenes look inside the heart of global disaster response facility - Launches on World Humanitarian Day, 19 August 2025 - First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank DUBAI, UAE, Aug. 19, 2025 -- Dubai Humanitarian, the world's largest humanitarian logistics hub, has unveiled a new documentary, Coming Together: The Dubai Humanitarian Story - a gripping behind-the-scenes look at the premier disaster response faci
- 김갑성 기자
- 2025-08-19 17:00
Nilesh Shah joins Illumina as Head of Region, AMEA

SINGAPORE, Aug. 19, 2025 -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately. Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having held senior roles at Johnson & Johnson, GE Healthcare and most recently, West Pharmaceutical Services. At West, he served as Vice President & General Manager, Emerging Markets, where he led commercial, operational, and manufacturing st
- 김갑성 기자
- 2025-08-19 14:14
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

SHANGHAI and HONG KONG, Aug. 19, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of CLDN18.2-positive, HER-2 negative unre
- 김갑성 기자
- 2025-08-19 13:26
Tigermed Receives MSCI ESG AAA Rating

HANGZHOU, China, Aug. 19, 2025 -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.
- 김갑성 기자
- 2025-08-19 11:15
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease

[ 메디채널 김갑성 기자 ] Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through six months (180 days). [2], [3] Administration can be timed during the first year of life to provide protection from birth, or as early as possible. SINGAPORE, Aug. 19, 2025 -- The Health Sciences Authority (HSA)
- 김갑성 기자
- 2025-08-19 11:00
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

YANTAI, China, Aug. 19, 2025 -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietna
- 김갑성 기자
- 2025-08-19 08:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 13시 00분